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Abstract
Treatment of EGFR-mutant non-small cell lung cancer patients with the tyrosine kinase inhibitors erlotinib or gefitinib results
in high response rates and prolonged progression-free survival. Despite the development of sensitive mutation detection
approaches, a thorough validation of these in a clinical setting has so far been lacking. We performed, in a clinical setting, a
systematic validation of dideoxy ‘Sanger’ sequencing and pyrosequencing against massively parallel sequencing as one of
the most sensitive mutation detection technologies available. Mutational annotation of clinical lung tumor samples
revealed that of all patients with a confirmed response to EGFR inhibition, only massively parallel sequencing detected all
relevant mutations. By contrast, dideoxy sequencing missed four responders and pyrosequencing missed two responders,
indicating a dramatic lack of sensitivity of dideoxy sequencing, which is widely applied for this purpose. Furthermore,
precise quantification of mutant alleles revealed a low correlation (r
2=0.27) of histopathological estimates of tumor content
and frequency of mutant alleles, thereby questioning the use of histopathology for stratification of specimens for individual
analytical procedures. Our results suggest that enhanced analytical sensitivity is critically required to correctly identify
patients responding to EGFR inhibition. More broadly, our results emphasize the need for thorough evaluation of all
mutation detection approaches against massively parallel sequencing as a prerequisite for any clinical implementation.
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Introduction
Initially limited to rare tumors such as chronic myeloid
leukemia (CML) or gastrointestinal stromal tumors (GIST), the
success of treating mutationally activated kinases with kinase
inhibitors has reached the group of the frequent ‘‘solid’’ tumors
and has thereby profoundly changed clinical oncology. Treat-
ment of patients suffering from EGFR-mutant cancers with
EGFR inhibitors leads to objective response [1,2,3], to a
doubling in progression-free survival as compared to standard
chemotherapy and to long overall survival [4,5]. Similar pairs of
genomic lesions and targeted drugs are BRAF mutation and
BRAF inhibition [6] PARP inhibition and BRCA1/BRCA2
mutations [7,8] or PDGFRA/KIT mutation and imatinib [9].
In light of the current efforts to systematically sequence the
genomes of all major tumor types (http://www.icgc.org/ or
www.cancergenome.nih.gov), the list of genetically defined
tumors that are susceptible to a specific therapeutic intervention
is likely to expand dramatically in the next few years. Together,
these observations suggest a rapidly growing need for sensitive
and accurate mutation detection in clinical specimens as part of
routine clinical care.
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tion of mutation detection encounters both sample-related and
methodological problems: first, the majority of clinical samples
available are small-sized, formalin-fixed and paraffin-embedded
(FFPE) biopsies or cytological specimens typically yielding limited
amounts of low quality DNA, all of which seriously affect PCR
amplification and subsequent analyses. Furthermore, the tumor
composition as well as multiple types of non-neoplastic cells affect
the detection of tumor-specific somatic mutations in a background
of non-mutant, ‘‘wild-type’’ alleles. Second, conventional sequenc-
ing approaches lack sensitivity for the detection of such rare alleles.
Several methods were established to offer sensitive mutation
detection, all including DNA extraction, PCR amplification and
subsequent mutation analysis by sequencing or genotyping-based
assays [10,11,12,13,14,15,16,17,18,19]. In several instances,
enrichment of tumor cells is achieved prior mutation detection,
e.g., by laser-assisted microdissection of tumor specimens [15,17].
Unfortunately, there is an almost universal lack of validation of
clinically relevant mutation detection approaches in clinical
settings against a sensitive gold standard approach.
We have recently introduced massively parallel sequencing for
mutation detection in clinical cancer specimens [20]. Such
approaches are widely considered to provide the highest sensitivity
currently available for this purpose due to the ability to sample
rare mutant alleles in a predominant background of wild-type
alleles in any tumor specimen [20]. Furthermore, this approach is
not restricted to an a-priori selection of mutations considered
relevant. Therefore, massively parallel sequencing is ideally suited
to validate other mutation detection methodologies.
In this study, we have validated two sequencing-based mutation
detection approaches (dideoxy- and pyrosequencing) against
parallel sequencing in a clinical setting, taking into account the
tumor cell content as well as the quality and the type of tissue (e.g.
FF, FFPE) of each specimen.
Materials and Methods
Ethics Statement
This study was approved by the Ethics Committee of the
Faculty of Medicine of the University of Cologne and all patients
gave written informed consent. A subgroup of patients (n=9)
participated in the ERLOPET trial (NCT00568841).
Tumor samples and cell lines
In this study, we have analyzed 24 tumor samples obtained from
22 patients (Table 1). This study was approved by the local Ethics
Committee and all patients gave written informed consent. A
subgroup of patients (n=9) participated in the ERLOPET trial
(NCT00568841). Tumor specimens were reviewed by a reference
pathologist to determine the tumor-cell content for subsequent
dissection of areas with highest tumor-cell content. NSCLC cell
linesharbouringdifferentEGFRandKRASmutationswereobtained
and cultured as described previously (Supplementary Table S1)
[21]. Genomic DNA of all tumor specimens and cell lines was
extracted using Gentra Pure Gene Tissue Kit (Qiagen) followed by
DNA quantification using Picogreen dsDNA reagents (Invitrogen).
PCR and direct dideoxy sequencing
EGFR exon18–21 and KRAS exon 2 and 3 were amplified by
nested PCR and gene specific external and internal primer pairs
(Supplementary Table S2). Internal primers are equipped with
the M13-primer sequence to facilitate sequencing. For external PCR
reactions, we used 5–10 ng (40–60 ng low quality DNA) of genomic
DNA. PCR reactions were carried out in a total volume of 50 ml
(0.2 mM of each primer, 2 mM MgCl2,2 0 0mMo fe a c hd N T Pa n d
1.25 U HotStarTaq Plus DNA Polymerase KIT (Qiagen)) and the
following cycling conditions: 95uCf o r5m i n ,3 0c y c l e sa t9 5 uCf o r
30 sec, 60uC for 30 sec and 72uC for 1 min and final extension at
72uC for 10 min. After ExoSAP-IT (USB Corporation) treatment
PCR products were bidirectional sequenced using the M13-
sequencing primers and BigDye Terminator Mix version 3.1
(Applied Biosystems) on ABI 3730 (Applied Biosystems). Sequencing
electropherograms were analyzed by visual inspection of electro-
pherogramsandbyMutationSurveyor2.03Software(SoftGenetics).
Fragment length analysis of EGFR exon 19 was carried out by
standard PCR (For-Hex-ctggatccagaaggtgaga and Rev-ccacacag-
caaagcagaaac) resulting inamplicons of118-bp(Ta=59uC)for wild-
type exon 19. PCR products were analyzed on ABI 3700 DNA
sequencer and scored by GeneMarker software (SoftGenetics).
Pyrosequencing assays
We have designed five different pyrosequencing [22] assays for
sequencing analysis of EGFR exon 19–21 and KRAS exon 2 and 3
(Supplementary Table S3). Template DNA (6 ng genomic
DNA or external PCR products) was amplified using HotStarTaq
Plus DNA Polymerase KIT (Qiagen) and standard protocol
(0.2 mM of each primer, 160 mM dNTPs, 2 U enzyme) and
cycling conditions (45 cycles and Ta=59uC for EGFR exon 19,
Ta=60uC for KRAS exon 2, Ta=63uC for EGFR exon 20,
Ta=61uC for EGFR exon 21 and KRAS exon 3 and Ta=60uC for
KRAS exon 2). Reverse PCR primers were biotinylated for
subsequent pyrosequencing analysis. Pyrosequencing reactions
were carried on PSQ HS96A instrument using PSQ HS96A SNP
reagents and pyrosequencing SNP analysis software (Biotage AB,
Uppsala, Sweden, now named PyroMark
TMQ96MD by Qiagen).
For sensitivity studies, quantified PCR products of EGFR-mutant
cells or KRAS-mutant cells were diluted with wild-type EGFR or
wild-type KRAS amplicons, respectively. Pyrosequencing raw data
signals were normalized using known wild-type signals. Significant
mutation calling was determined from experimental noise by
statistical analysis of raw data using T-test (p#0.05).
Massively parallel sequencing analysis
Massively parallel sequencing was performed using the GS FLX
Standard or GS FLX Titanium chemistry according to standard
protocols (Roche). Amplicon libraries were generated using
external PCR products as templates and standard protocols and
conditions of FastSTart Hifi PCR system (Roche) (Supplemen-
tary Table S4). We used on average 340.000 beads per run
yielding 80.000–120.000 reads in total and an amplicon coverage
ranging from 6006to 15006with an average amplicon length of
250–300 bp covering the entire exon. All reads were aligned to
chromsome 7 and 12 of the reference genome (hg18) using BWA
[23]. Finally, aligned reads were visualized and analyzed by the
Integrative Genomics Viewer (http://www.broadinstitute.org/
igv/). The Students T test was used for comparison of relative
read frequency between EGFR mutated and wildtype tumors. We
set the sequencing error rate to 0.1% in areas without
homopolymers [24]. The threshold for significant detection of
mutated alleles was defined using a Poisson distribution of the
known error rate taking into account the coverage leading to a
detection limit between 0.3 and 0.5% mutant alleles.
Results
Patients and tumor specimens
From September 2008 to April 2009, we have analyzed patients
with histologically confirmed NSCLC for the presence of
EGFR Mutation Detection in NSCLC
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Patients enrolled in this mutation analysis study are not
representative for the prevalence of such mutations in NSCLC
as they were enriched for cases with an increased likelihood of
being EGFR mutation-positive based on histological and clinical
features (e.g., lung adenocarcinoma in never or light ex-smokers).
In this benchmarking study, we have analyzed 24 tumors from 22
patients (Table 1) for a systematic comparison of mutation
detection performance of conventional dideoxy- and pyrosequenc-
ing against one of the most sensitive sequencing technology,
massively parallel sequencing [20]. The tumor-cell content of each
of these specimens was estimated by a pathologist and ranged from
5% to up to 95%. Clinical specimens comprised formalin-fixed
and paraffin-embedded (FFPE) tumor tissue blocks as well as fresh-
frozen (FF) biopsies or cytological slides obtained from pleural
effusions (Table 1).
Table 1. Clinical characteristics and genomic alterations in NSCLC specimens.
case
histo
type sex age
tissue
type specimen type
tumor
content
(%)
allel
(%)
TKI
resp. dideoxy pyro parallel mutation
01 AD M 38 FF wedge Bx 80 N/A SD WT WT WT no mutation
14 SQ M 67 FFPE transbronchial Bx 95 N/A SD WT WT WT no mutation
21 SQ M 39 FFPE Bx of chest wall 90 N/A PD WT WT WT no mutation
26 AD M 60 H&E pleural effusion 5 N/A PD WT
* WT
* WT no mutation
28 AD F 69 FF lung surgery 70 N/A N/A WT WT WT no mutation
33 AD M 61 FFPE transbronchial Bx 80 N/A N/A WT WT WT no mutation
34 AD M 44 FFPE lung surgery 80 N/A N/A WT WT WT no mutation
02 AD F 69 FFPE CT-guided lung Bx 50 54 PR MUT MUT MUT EGFR exon 19 E746_A750del
(Del-1a)
03 AD M 58 FFPE cerebral surgery 80 30 PR MUT MUT MUT EGFR exon 21 L858R
04 SQ M 58 FFPE transbronchial Bx 80 58 PR MUT MUT MUT EGFR exon 19 E746_T751del,
S752V
05 AD M 76 FFPE mediastinoscopy 50 11 PR WT MUT MUT EGFR exon 19
E746_R748del,A750P
06
a) AD M 40 FF cervical LN Bx 70 36 PR MUT MUT MUT EGFR exon 19 E746_A750del
(Del-1b)
06
b) AD M 40 CSF lumbar puncture N/A 68 RL MUT MUT MUT EGFR exon 19 E746_A750del
(Del-1b)
08 AD F 52 FFPE supraclavicular LN Bx 80 49 PR MUT MUT MUT EGFR exon 19 E746_A750del
(Del-1b)
10
b) AD F 63 FF Liver Bx 80 95 PR MUT MUT MUT EGFR exon 19 L747_S752del,
P753S
10
b) AD F 63 FF Liver Bx 80 20 RL
$ WT MUT MUT EGFR exon 20 T790M
12 AD F 80 FF lung sugery 90 52 PR MUT MUT MUT EGFR exon 19 E746_A750del
(Del-1a)
13
a) AD M 62 H&E pleural effusion 5 8 PR WT WT MUT EGFR exon 19 L747_A750del,
T751P
13
b) AD M 62 FF pleural effusion 70 74 RL MUT MUT MUT EGFR exon 19 L747_A750del,
T751P
27 AD F 71 FF CT-guided lung Bx 40 11 PR WT MUT MUT EGFR exon 19 E746_A750del
(Del-1a)
31 AD F 66 FF transbronchial Bx 60 6 PR WT WT MUT EGFR exon 19 E746_A750del
(Del-1b)
11 AD M 55 FFPE lung surgery 50 21 N/A WT MUT MUT KRAS exon 2 G12A
19 AD F 52 FFPE lung surgery 50 36 SD MUT MUT MUT KRAS exon 2 A11V; G12V
24 AD M 69 FFPE lung surgery 95 40 PD MUT MUT MUT KRAS exon 2 G13C
30 AD F 61 FFPE lung surgery 35 29 PD MUT MUT MUT KRAS exon 2 G12V
Abbreviations: AD, adenocarcinoma; Bx, biopsy; CSF, cerebral-spinal fluid; Del, deletion in EGFR exon 19 (Del-1a: E746_A750_2235–2249del; Del-1b: E746_A750_2236–
2250del); F, female; FF, Fresh-Frozen; FFPE, Formalin-fixed, paraffin-embedded; H&E, haematoxylin and eosin-stained tumor section; M, male; LN, lymph node; N/A, not
applicable; MUT, mutation; PD, progressive disease; PR, partial remission; RL, relapse; SD, stable disease; SCLC, small cell lung cancer; SQ, squamous cell carcinoma; TKI,
tyrosine kinase inhibitor; WT, wild-type EGFR and KRAS;
a)Tumor specimen obtained prior to TKI treatment.
b)Tumor specimen obtained after relapse from TKI treatment.
*Mutation detection sensitivity of dideoxy and pyrosequencing is limited due to rare tumor cell content possibly generating false-negative samples.
$Case 10 achieved a partial response to TKI treatment. However, the analyzed tumor specimen was obtained at the time of relapse and is therefore indicated as PR
(partial remission) and RL (relapse).
doi:10.1371/journal.pone.0019601.t001
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different sensitivity
We first performed conventional dideoxy-nucleotide chain
termination-based (‘‘Sanger’’) sequencing on all of these specimens
because, despite its limitations, this method is still the most widely
used approach for mutation detection in clinical specimens. We
determined the sensitivity of this sequencing technique to range
from 20–30% of mutated alleles by mixing PCR products of
KRAS-mutant and wild-type cell lines (Supplementary Fig. S1).
Mutation screening of 24 tumor samples by dideoxy sequencing
revealed short in-frame nucleotide deletions in EGFR exon 19
(Table 1, Fig. 1A and 1B) in eight samples and only one sample
(case 03) harbored the L858R point mutation in exon 21 of EGFR
(Table 1). Moreover, three samples (case 19, 24 and 30) had
mutations in exon 2 of the KRAS gene (Table 1).
We next tested whether conventional pyrosequencing [22] was
able to confirm mutations found by dideoxy sequencing and if
additional mutations could be found by this method in the patient
cohort tested. Pyrosequencing offers cost-effective quantitative
detection of sequence variants and was previously shown to enable
sensitive KRAS mutation detection in colorectal cancer [12,25,26].
The enhanced sensitivity for detection of rare variants is due to the
generation of non-interfering, individual signals for mutant and
wild-type alleles. We established sensitive (5–10% mutant allele),
reproducible and linear pyrosequencing assays for the most
prominent mutation hotspots in EGFR and KRAS (Supplemen-
tary Fig. S2, S3, S4, S5, S6, S7, S8, S9, S10). Pyrosequencing
confirmed all mutations detected by dideoxy sequencing (Table 1).
However, we also detected four additional mutations in our
sample cohort that had been missed by dideoxy sequencing
(Table 1, Fig. 1C and Supplementary Fig. S3A, S6B, S9A).
For example, we detected the erlotinib resistance mutation,
T790M, in tumor sample 10 (80% tumor cell content) obtained
at the time of relapse (Supplementary Fig. S6B) and this
sample also harbored the L747_S752del_P753S deletion initially
detected by dideoxy sequencing (Table 1 and Fig. S4C). We
further found a previously undetected G12A substitution in exon 2
of KRAS in sample 11 (50% tumor cell content, Supplementary
Fig. S9A) and confirmed this mutation by subcloning of KRAS
exon 2 amplicons and subsequent dideoxy sequencing (data not
shown). EGFR exon 19 pyrograms of sample 27 (40% tumor cells)
and of sample 05 (50% tumor cells) exhibited fluorescence signals
indicative for the presence of mutations that were significantly
above the level of experimental noise (Fig. 1C and Supple-
mentary Fig. S3A). Fragment-length analyses of EGFR exon 19
PCR products validated this deletion in sample 27 (Supplemen-
tary Fig. S11).
Finally, we employed massively parallel array-based pyrose-
quencing-by-synthesis [20] to validate mutation results obtained
by conventional dideoxy and pyrosequencing. We sequenced all of
the 24 specimens to an average coverage of 10796 and a
minimum coverage of 6006per exon and specimen. Data analysis
confirmed the presence of EGFR and KRAS mutations in 13
samples initially identified by both, dideoxy sequencing and
pyrosequencing (Table 1). Furthermore, massively parallel
sequencing also validated the four additional mutations that were
newly detected by sensitive pyrosequencing: EGFR exon 19
deletions in sample 05 and 27, the G12A mutation of KRAS in
sample 11 and the T790M mutation of EGFR in sample 10
(Table 1). The parallel nature of this sequencing approach
enabled precise quantification and identification of these low-
frequency variants. Specifically, we identified the exon 19
mutation in sample 05 to be a 9-bp in-frame deletion encoding
the amino acid deletion-substitution E746_R748del_A750, at a
frequency of 11% of 1315 reads (Table 1). Furthermore, we
quantified a 12-bp deletion (E746_A750) to occur at a frequency
of 11% of 854 reads in sample 27 (Fig. 1C). The G12A
substitution in sample 11 was present in 21% of 1358 reads and
the T790M resistance mutation in sample 10 occurred at a
frequency of 20% out of 909 reads (Table 1).
In addition to validating the previously detected mutations
parallel sequencing identified EGFR exon 19 deletions in sample
31 and 13a, which were indistinguishable from experimental noise
in both conventional dideoxy and pyrosequencing analyses.
Parallel sequencing enabled the detection of an E746_A750del
in sample 31 at a frequency of 6% of 1081 reads (Table 1 and
Fig. 1D). Remarkably, this specimen had been estimated to
contain 60% tumor cells by histopathology (Table 1). Similarly,
flowgrams of sample 13a (5% tumor cells) revealed a 12-bp
deletion (L747_A750del_T751P) at a frequency of approximately
8% of 658 reads (Table 1). This mutation was identical to the one
already detected by dideoxy sequencing in another specimen of
the same patient (samples 13b) with higher tumor content (70%),
obtained at the time of relapse (Table 1). Thus, beyond validating
all of the other mutations that had been called by dideoxy
sequencing (n=12) and pyrosequencing (n=16), massively
parallel sequencing identified two further mutated samples that
had been missed by the other two methods due to insufficient
sensitivity (Table 1 and Supplementary Table S5).
We next analyzed high-quality 454 sequencing reads (phred
score .30) with the goal of detecting T790M mutations occurring
at low frequency in specimens obtained before therapy. Exon 20
was covered to an averaged depth of 1018 reads in the region of
codon 790. In patients whose tumors had a deletion in exon 19 or
L858R we observed a significantly higher (p=0.03) number of
reads containing the T790M mutation as compared to patients
with wildtype EGFR (EGFR mut: mean=2.5/1000; range 0–7.5/
1000; EGFR wt: mean 0.8/1000 (0–2.3/1000). We note that these
allele frequencies are in the range of the technological limit of
accuracy. However, the number of reads with T790M was above
the threshold for mutation calling in 27% of the samples with
deletion in exon 19 or L858R but in no sample without EGFR
mutation (Supplementary Fig. S12).
Taken together, massively parallel sequencing identified a total
of 18 mutations in EGFR and KRAS resulting in a sensitivity of
67% for dideoxy sequencing and 89% for pyrosequencing
(Table 1 and Supplementary Table S5). Despite the limited
size of our sample set, these results underscore the dramatic lack of
sensitivity of dideoxy sequencing in clinical mutation detection.
Sensitivity of mutation detection as a function of tumor
cell content
Tumor-cell content is a critical parameter for the performance
of mutation detection in cancer [20] and is the basis for
microdissection-based tumor-cell enrichment. We therefore sought
to analyze the performance of the three mutation analysis methods
as a function of histopathologically estimated tumor-cell content.
The mean tumor content of samples identified as being mutant by
dideoxy sequencing was 78% (range 35–95%) and 71% (range 35–
95%) in the case of pyrosequencing (Fig. 2A). All samples, in
which dideoxy sequencing had missed mutations, contained 80%
tumor cells or less. By contrast, the specimens in which
pyrosequencing had missed mutations had 60% tumor content
or less (Fig. 2A).
We next assessed the correlation between tumor-cell content
and frequency of mutated alleles as determined by massively
parallel sequencing (Fig. 2A). We observed a low correlation
between the analytically determined allele frequency and the
EGFR Mutation Detection in NSCLC
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2=0.27, p=0.029). Remarkably, the detec-
tion limits of the different approaches determined by counting of
mutant and wild-type alleles detected by massively parallel
sequencing in the primary tumors were highly similar to those
observed in the initial allele mixing experiments (Supplementa-
ry Figs. S2, S3, S4, S5, S6, S7, S8, S9, S10): 29% for dideoxy
sequencing and 11% for pyrosequencing (Table 1 and Fig. 2A).
The allele frequencies of mutations found by pyrosequencing but
not dideoxy sequencing ranged between 11% and 21% (Fig. 2A).
Mutations only detected by massively parallel sequencing occurred
Figure 1. EGFR exon 19 mutation analysis in NSCLC tumor samples. Sequencing analysis of EGFR exon 19 was performed by dideoxy
sequencing (electropherograms in the left panels), pyrosequencing (pyrogams in the middle panels) and massively parallel sequencing (programs in
right panel). (A) Wild-type EGFR exon 19 detected by all three sequencing techniques; (B) L747_A750del, P753S mutation detected by all three
sequencing techniques; (C) E746_A750del (Del-1A) mutation identified by pyrosequencing and massively parallel sequencing; (D) E746_A750del (Del-
1B) only detected by massively parallel sequencing. del, deletion; Mut, mutation; WT, wild-type. Arrows indicate position of expected mutation
specific signals.
doi:10.1371/journal.pone.0019601.g001
EGFR Mutation Detection in NSCLC
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Strikingly, the tumor content in these cases had been estimated to
be 60% and 5%, respectively. Thus, histopathological estimates of
tumor-cell content are not predictive of the frequency of mutant
alleles, while the ability to detect mutations is limited by the allele
frequency but not by the tumor cell content.
EGFR mutations and clinical outcome
Previous analyses of the association of EGFR mutations and
clinical benefit induced by EGFR inhibition has occasionally
yielded inconsistent results in that some studies have reported a
lack of such association [27,28,29] Such inconsistencies might
result from the failure to detect mutations with sufficient
sensitivity and accuracy. Importantly, in our cohort, only
massively parallel sequencing was able to detect a sensitizing
EGFR mutation in all patients that had experienced a partial
response (according to RECIST criteria) following treatment with
erlotinib (Fig. 2B). By contrast, only 7 out of 11 patients with
confirmed PR were detected by dideoxy sequencing and 9 of 11
were identified by pyrosequencing (Fig. 2B). Thus, despite the
limited size of our patient cohort, these results support the notion
that the dramatic differences in sensitivity strongly skew the
association between the presence of EGFR mutations and
response to erlotinib. Patients with EGFR-wild-type tumors and
KRAS-mutant tumors who had received erlotinib exhibited stable
or progressive disease (Table 1) in accordance with previous
reports [30].
Discussion
Here, we show how the limited sensitivity of methods that are
widely applied to clinical mutation diagnostics could lead to a
critical inaccuracy in genetic patient stratification. In particular,
the low sensitivity of dideoxy sequencing led to misdiagnoses in 6
of 24 lung cancer specimens. If the presence of an EGFR
mutation had been the inclusion criterion for treatment with
EGFR inhibitors, four patients would not have received the right
treatment. Thus, despite the limited size of our sample set, these
results underscore the inadequacy of dideoxy sequencing for
clinical cancer gene mutation diagnostics. By contrast, conven-
tional pyrosequencing offered enhanced sensitivity with only two
patients being misdiagnosed. Furthermore, massively parallel
sequencing robustly and accurately identified all mutations
present in the dataset. We further show that parallel sequencing
can detect preexisting T790M mutations in a 27% fraction of
EGFR-mutant patients [31]. These results support the conclusion
that massively parallel sequencing is the most sensitive technology
currently available in clinical mutation diagnostics and suggest
that pyrosequencing might be an alternative to dideoxy
sequencing.
While many techniques have emerged over the past few years to
match the ever-growing need to provide accurate clinical mutation
analyses to oncologists, none of these have been systematically
benchmarked against massively parallel sequencing, the method
with the highest sensitivity for clinical mutation detection to date.
Extrapolating differences such as those observed in this study to
the large number of cancer patients worldwide indicates that many
patients are being misdiagnosed each year. Thus, carefully
developed diagnostic approaches (including thorough validation
against massively parallel sequencing) will help targeting effective
treatment to the right patient population.
Microdissection has been applied widely to increase the
fraction of tumor cells in a given specimen in order to enhance
the sensitivity of dideoxy sequencing. Identification of tumor-
rich areas is a prerequisite for such procedure. We found,
however, only a low correlation of tumor-cell content and
frequency of mutant alleles. We assume that a routine survey of
histopathological sections cannot accurately estimate the degree
of ‘‘contamination’’ of the mutant allele by healthy bystander
cells (e.g. normal lung tissue), that obscure the frequency of the
mutant allele. Thus, microdissection can only partially rescue
the limited sensitivity of dideoxy sequencing and should
t h e r e f o r ea l s ob ev a l i d a t e dc a r e fully against massively parallel
sequencing.
Another frequently discussed topic is the question of whether
genotyping or sequencing might be the optimal strategy for
clinical mutation detection in cancer. Even though our results
s u g g e s tt h a tp y r o s e q u e n c i n gi sasensitive, accurate and cost-
effective method to analyze the vast majority of samples with a
tumor content of 20–70%, other methods, including those based
on genotyping, might perform equally well. In case of already
known hot-spot mutations locked nucleic acid (LNA) approach-
es are able to detect mutant alleles occurring at frequencies as
Figure 2. Mutation detection performance in NSCLC tumor
samples using dideoxy sequencing, pyrosequencing and
massively parallel sequencing. (A) Correlation between the
estimated tumor cell content and the actual frequency of mutated
alleles determined by massively, parallel sequencing data. Black,
mutations detected by dideoxy and pyrosequencing; Green, mutations
detected by pyrosequencing, but missed by dideoxy sequencing; Red,
mutations only detected by parallel sequencing. (B) Sensitivity of
dideoxy sequencing, pyrosequencing and massively parallel sequenc-
ing in patients with confirmed clinical response to treatment with
erlotinib.
doi:10.1371/journal.pone.0019601.g002
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clinical application include immunohistochemistry using EGFR
mutation-specific antibodies [32] or the application of molecular
beacons coupled by fluorescent imaging [33]. However, it is
important to keep in mind that the intrinsic inability of
genotyping methods to cover all clinically relevant mutations,
adds to any analytical insensitivity. Based on these consider-
ations, we favor sequencing-based mutation detection over
genotyping. Although our sample size is too limited to
comprehensively calculate sensitivity and specificity of mutation
detection, we believe that the striking inferiority of conventional
Sanger sequencing to detect therapeutically relevant oncogene
mutations is of considerable interest to molecular pathologists
and clinical oncologists.
In summary, we have shown how sequencing technologies with
inferior sensitivity may fail to detect clinically relevant oncogene
mutations in cancer patients. We therefore conclude that any
novel method for clinical mutation diagnostics should be
thoroughly validated against massively parallel sequencing in
order to provide a correct genetic analysis as basis for molecularly
targeted therapy.
Supporting Information
Figure S1 Sensitivity study of dideoxy sequencing and
Pyrosequencing. Different mixtures of PCR products from
wild-type or G12S mutant NSCLC cell lines were used to
determine the sensitivity limit of dideoxy sequencing (,20–
30%) and pyrosequencing (,5%). Mutation specific signals are
marked by asterisks in dideoxy electropherograms (left panels)
and red arrows in programs (right panels). Mut, mutation; WT,
wild-type.
(TIF)
Figure S2 Sensitivity and linearity testing of the EGFR
exon 19 pyrosequencing assay. Mixtures of E746_A750del
(Del-1a) mutant and wild-type PCR products of NSCLC cell lines
were used to analyse the mutation detection limit and assay
linearity. The assay is sensitive to a minimum of 5 to 10% of
mutated alleles. Mutation specific signals are marked by red
arrows. del, deletion; Mut, mutation; WT, wild-type.
(TIF)
Figure S3 Pyrosequencing analysis of EGFR exon 19 in
NSCLC tumor samples. (A) EGFR exon 19 deletion identified
in sample with 50% tumor cell content that was previously not
identified by dideoxy sequencing; (B) No significant mutation
detection in sample 13a with a 5% tumor cell content. Expected
position of mutation specific signals is marked by red arrow. del,
deletion; Mut, mutation; WT, wild-type.
(TIF)
Figure S4 Pyrograms of EGFR exon 19 mutant NSCLC
cell line and tumor samples. (A) Del-B mutation in cell line
HCC827; (B–D) Tumor specimens with an high tumor cell
content enabling precise characterisation of the individual
mutation; (E, F) Tumor specimens with a moderate (50% and
80%) tumor cell content resulting in overlapping signals of
wild-type and mutant alleles. Mutation specific signals are
marked by red arrows. del, deletion; Mut, mutation; WT, wild-
type.
(TIF)
Figure S5 Sensitivity and linearity testing of the EGFR
exon 21 (L858R) pyrosequencing assay. (A) Mixture study of
PCR products from wild-type and L858R mutant NSCLC cell
lines to determine the assay sensitivity limit of 5%–10%; (B)
L858R point mutation identified in sample 03 (80% tumor cell
content). Mutation specific signals are marked by red arrows. Mut,
mutation; WT, wild-type.
(TIF)
Figure S6 Sensitivity and linearity testing of the EGFR
exon 20 (T790M) pyrosequencing assay. (A) Mixture study
of PCR products from wild-type and T790M mutant NSCLC cell
lines to determine the assay sensitivity limit of 5%–10%; (B)
T790M point mutation detected in sample 10 (80% tumor cell
content) that was previously not detected by conventional dideoxy
sequencing. Mutation specific signals are marked by red arrows.
Mut, mutation; WT, wild-type.
(TIF)
Figure S7 Sensitivity and linearity testing of the KRAS
exon 2 (G12X;G13X) pyrosequencing assay. Mixture study
of PCR products from wild-type and G12S KRAS exon 2 mutant
NSLC cell lines to determine the assay sensitivity limit 0f 5%–
10%. Mutation specific signals are marked by red arrows. Mut,
mutation; WT, wild-type.
(TIF)
Figure S8 Pyrograms of KRAS exon 2 mutant NSCLC
cell lines. (A) wild-type KRAS in H1650; (B) G12D in SKLU1;
(C) G12V in H2887; (D) G13C in H1355; (E) G12C in H2122; (F)
G12A in H2009. WT, wild-type.
(TIF)
Figure S9 Pyrograms of NSCLC tumor samples har-
bouring different KRAS mutations. (A) G12A in sample 11;
(B) A11V, G12V in sample 19; (C) G13C in sample 30 and (D)
G12V in sample 30. Mut, mutation; WT, wild-type.
(TIF)
Figure S10 Sensitivity and linearity testing of the KRAS
exon 3 (Q61X) pyrosequencing assay. Mixture study of PCR
products from wild-type and Q61H KRAS exon 3 mutant NSCLC
cell lines to determine the assay sensitivity limit of 10%. Mutation
specific signals are marked by red arrows. Mut, mutation; WT,
wild-type.
(TIF)
Figure S11 Fragment length analysis of EGFR exon 19
PCR products. (A) sample 27 harbouring a 15 bp deletion
(100 bp fragment); (B) wild-type EGFR exon 19 (115 bp fragment)
of sample 28.
(TIF)
Figure S12 Read frequency of T790M mutation in pre-
treatment tumor specimens. Depicted is the average read
frequency of T790M separately for EGFR wildtype and EGFR
mutated tumor specimens. Tumor specimen 10b with a high allele
frequency of T790M and clinical resistance to erlotinib treatment
is not shown in this diagram.
(PPT)
Table S1 EGFR and KRAS mutant NSCLC cell lines.
NSCLC cell lines harbouring different EGFR and KRAS
mutations with respective amino acid changes are shown.
(DOC)
Table S2 Primer sequences for EGFR and KRAS nested
PCR. External and internal primer sequences used for EGFR
exon18–21 and KRAS exon 2 and 3 PCR are shown.
(DOC)
Table S3 Primer sequences for EGFR and KRAS
pyrosequencing. Shown are primer sequences for five different
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19601pyrosequencing assays for sequencing analysis of EGFR exon 19–
21 and KRAS exon 2 and 3.
(DOC)
Table S4 EGFR and KRAS gene specific primers for
massively parallel sequencing. Primer pairs for massively
parallel sequencing of EGFR exon 18–21 and KRAS exon 2 and 3
are depicted.
(DOC)
Table S5 Comparison of mutation detection perfor-
mance between sequencing methods. Sensitivity of EGFR
and KRAS mutation detection by three different sequencing
technologies (dideoxy sequencing, pyrosequencing, parallel se-
quencing) is shown.
(DOC)
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